Centogene_Logo.png
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
March 19, 2024 06:30 ET | Centogene NV
Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 ...
Centogene_Logo.png
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 11, 2023 08:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
Centogene_Logo.png
CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
August 31, 2023 16:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers...
Centogene_Logo.png
CENTOGENE to Participate in Upcoming Conferences in August
August 07, 2023 06:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
Centogene_Logo.png
CENTOGENE Regains Compliance With Nasdaq Listing Requirements
July 14, 2023 06:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
Centogene_Logo.png
CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting
June 30, 2023 16:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
Centogene_Logo.png
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
June 27, 2023 07:30 ET | Centogene NV
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF) based in RiyadhJV...
Centogene_Logo.png
CENTOGENE Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
June 14, 2023 16:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers...
Centogene_Logo.png
CENTOGENE to Participate in Upcoming Conferences in May
May 05, 2023 06:30 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
Centogene_Logo.png
CENTOGENE to Participate in Upcoming Conferences in April
April 14, 2023 08:00 ET | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...